10.4 Cardiovascular Pharmacology in Podiatric Patients

10.4 Cardiovascular Pharmacology in Podiatric Patients

Independent Study Guide Notice: Independent study guide by OpenExamPrep. This educational resource is developed independently by OpenExamPrep and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

---

Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

Patients presenting to podiatric clinics for diabetic limb salvage, reconstructive foot and ankle surgery, or peripheral vascular disease overwhelmingly carry comorbid hypertension, diabetes mellitus, and heart failure managed with RAAS antagonists.

                         The RAAS Pathway & Drug Targets
   Angiotensinogen (Liver)
         │
         ▼ ◄─── [Renin] (Renal Juxtaglomerular Cells; Blocked by Aliskiren)
   Angiotensin I
         │
         ▼ ◄─── [ACE / Kininase II] (Pulmonary Endothelium; Blocked by ACE Inhibitors)
   Angiotensin II (Potent Vasoconstrictor; Efferent Arteriolar Constriction)
         │
         ├───────────────────────────────┬───────────────────────────────┐
         ▼                               ▼                               ▼
     AT1 Receptors                 Adrenal Cortex                   Bradykinin
  (Blocked by ARBs)             (Aldosterone Secretion)          (Degraded by ACE)
         │                               │                               │
         ▼                               ▼                               ▼
  Vasoconstriction              Na+/H2O Retention (Late DCT)     [Inhibited by ACEI]
  ↑ SVR & Afterload             K+/H+ Excretion (Collecting)     Accumulates → Cough &
  Efferent Constriction         [Blocked by Spironolactone]      Angioedema

Angiotensin-Converting Enzyme (ACE) Inhibitors

• Representative Agents: Lisinopril, Enalapril, Ramipril, Captopril, Benazepril.
• Mechanism of Action: Competitively inhibit Angiotensin-Converting Enzyme (ACE), a zinc metallopeptidase situated primarily on pulmonary vascular endothelial luminal membranes. ACE is identical to the enzyme kininase II.
  • Blocks conversion of inactive Angiotensin I $\rightarrow$ active Angiotensin II, decreasing systemic vasoconstriction, total peripheral resistance, and blood pressure.
  • Reduces Angiotensin II-stimulated secretion of Aldosterone from the adrenal zona glomerulosa, promoting renal natriuresis while retaining potassium.
  • Inhibits Bradykinin and Substance P Degradation: Because ACE (kininase II) normally inactivates bradykinin, ACE inhibition causes dramatic systemic and airway accumulation of bradykinin and substance P.
• Renal Hemodynamics & Diabetic Nephropathy Protection:
  • In healthy kidneys, Angiotensin II preferentially constricts the efferent arteriole of the glomerulus, elevating glomerular capillary hydrostatic pressure ($P_{GC}$) and preserving Glomerular Filtration Rate (GFR).
  • ACE inhibitors block this mechanism, producing selective efferent arteriolar vasodilation. This reduces intraglomerular capillary pressure, diminishes hyperfiltration injury, and significantly slows the progression of proteinuria and renal fibrosis in Diabetic Nephropathy.
• Adverse Effects:
  • Dry, Non-Productive Cough (5% - 20%): Mediated by local bronchial accumulation of bradykinin, substance P, and prostaglandins irritating pulmonary sensory C-fibers. Unrelated to dose; resolves within 1–4 weeks of drug cessation.
  • Angioedema (0.1% - 0.7%): Rapid-onset, non-pitting, non-pruritic transudative swelling of the lips, tongue, pharynx, larynx, and face mediated by bradykinin-induced microvascular leakage. Can cause acute airway obstruction; contraindicated permanently if experienced.
  • Hyperkalemia: Reduced aldosterone decreases $Na^+/K^+$ exchange in the principal cells of the cortical collecting duct, elevating serum potassium.
  • Acute Decline in GFR in Bilateral Renal Artery Stenosis: In patients with severe bilateral renal artery stenosis (or stenosis in a solitary kidney), renal perfusion pressure is severely compromised, and GFR is maintained exclusively by Angiotensin II-mediated efferent arteriolar constriction. ACE inhibitors abruptly eliminate this efferent tone, precipitating an acute, dramatic drop in GFR and acute renal failure.
  • Teratogenicity: Causes fetal renal tubular dysgenesis, oligohydramnios, skull hypoplasia, and fetal demise (contraindicated in pregnancy).

Angiotensin Receptor Blockers (ARBs)

• Representative Agents: Losartan, Valsartan, Candesartan, Irbesartan.
• Mechanism of Action: Potent, competitive antagonists that selectively block the Angiotensin II Type 1 ($AT_1$) receptor. They block all downstream actions of Angiotensin II (vasoconstriction, aldosterone release, vascular remodeling) without altering ACE activity.
• Clinical Distinction from ACEIs: Because ARBs do not inhibit kininase II, they do NOT cause accumulation of bradykinin or substance P. Consequently, ARBs do not cause the dry brassy cough characteristic of ACE inhibitors and exhibit a markedly lower incidence of angioedema. They are the drug of choice for patients requiring RAAS blockade who develop ACEI-induced cough. They share the same risks of hyperkalemia, acute GFR drops in renal artery stenosis, and teratogenicity.

Calcium Channel Blockers (CCBs) & The Podiatric Edema Pearl

Calcium channel blockers inhibit voltage-gated L-type (long-lasting) calcium channels ($Ca_V1.2$) in cardiac myocytes, specialized conducting nodal tissue, and vascular smooth muscle, decreasing intracellular calcium entry and inhibiting contraction.

Dihydropyridine vs. Non-Dihydropyridine CCBs

Diuretic Pharmacotherapy & Podiatric Board Correlations

Diuretics alter tubular solute and water transport along distinct nephron segments. Their metabolic and electrolyte disturbances directly affect lower extremity clinical presentations, particularly gout and wound healing.

                                Nephron Diuretic Sites
   Glomerulus
       │
       ├─► Proximal Convoluted Tubule: Carbonic Anhydrase Inhibitors (Acetazolamide)
       │
       ├─► Thick Ascending Limb (Loop of Henle): Loop Diuretics (Furosemide, Torsemide)
       │   [Inhibits NKCC2 Cotransporter; Causes 'Loops Lose Calcium']
       │
       ├─► Early Distal Convoluted Tubule: Thiazide Diuretics (HCTZ, Chlorthalidone)
       │   [Inhibits NCCT Cotransporter; Causes Calcium Retention]
       │
       └─► Cortical Collecting Tubule: K+-Sparing Diuretics (Spironolactone, Amiloride)
           [Inhibits Aldosterone / ENaC; Causes Hyperkalemia]

Loop Diuretics: Furosemide, Bumetanide, Torsemide, Ethacrynic Acid

• Mechanism: Reversibly inhibit the $Na^+/K^+/2Cl^-$ cotransporter (NKCC2) localized to the luminal membrane of the thick ascending limb of the loop of Henle. By halting sodium and chloride reabsorption, they eliminate the hypertonic medullary osmotic gradient, rendering the collecting duct unable to concentrate urine and inducing profound, rapid natriuresis.
• Calcium Handling: Disruption of the NKCC2 transporter halts the back-diffusion of potassium into the tubular lumen, abolishing the positive lumen-potential ($+10\text{ mV}$) that normally drives paracellular reabsorption of divalent cations. Consequently, "Loops Lose Calcium", leading to increased urinary calcium excretion (useful in hypercalcemia crisis).
• High-Yield Adverse Effects:
  • Hypokalemic, hypochloremic metabolic alkalosis and hypomagnesemia.
  • Hyperuricemia & Acute Gout Precipitation: Loop diuretics induce volume depletion, which stimulates proximal tubular reabsorption of urate. Furthermore, loop diuretics actively compete with uric acid for secretory organic acid transporters (OAT1/3) in the proximal tubule. This elevates serum uric acid, frequently precipitating an acute attack of gouty arthritis (podagra) in the first metatarsophalangeal joint of podiatric patients.
  • Ototoxicity: Dose-dependent damage to hair cells within the stria vascularis of the inner ear, presenting with tinnitus, vertigo, and reversible or permanent sensorineural hearing loss; exacerbated when combined with aminoglycosides.
  • Sulfa Allergy: Furosemide, bumetanide, and torsemide contain a sulfonamide moiety. In patients with severe sulfa allergy, the non-sulfonamide phenoxyacetic acid derivative Ethacrynic Acid must be utilized.

Thiazide Diuretics: Hydrochlorothiazide, Chlorthalidone, Metolazone

• Mechanism: Inhibit the $Na^+/Cl^-$ cotransporter (NCCT) in the luminal membrane of the early distal convoluted tubule (DCT).
• Calcium Handling: In sharp contrast to loop diuretics, thiazides enhance calcium reabsorption in the DCT by lowering intracellular sodium and stimulating the basolateral $Na^+/Ca^{2+}$ exchanger. This produces hypercalcemia (beneficial in osteopenic elderly patients and for preventing calcium oxalate nephrolithiasis).
• High-Yield Adverse Effects:
  • Hyperuricemia: Competes for organic acid excretion and elevates urate reabsorption, triggering acute gout attacks.
  • Hyperglycemia: Impairs pancreatic insulin release and decreases peripheral tissue glucose utilization; requires close glycemic monitoring in diabetic patients.
  • Hyperlipidemia, Hypokalemia, Hyponatremia.

Potassium-Sparing Diuretics

• Aldosterone Receptor Antagonists (Spironolactone, Eplerenone): Competitive inhibitors of cytoplasmic mineralocorticoid receptors in the principal cells of the cortical collecting tubule. Prevents aldosterone from upregulating epithelial sodium channels (ENaC) and basolateral $Na^+/K^+$ ATPases. Diminishes morbidity and mortality in severe systolic heart failure (HFrEF).
  • Adverse Effects: Hyperkalemia and metabolic acidosis. Spironolactone is a non-selective steroid antagonist that binds androgen and progesterone receptors, causing gynecomastia, breast tenderness, and erectile dysfunction in males. Eplerenone is highly selective for mineralocorticoid receptors and does not cause antiandrogenic side effects.
• Direct ENaC Blockers (Amiloride, Triamterene): Directly block luminal epithelial sodium channels (ENaC) in the collecting tubule, preventing sodium influx and secondary potassium excretion. Major risk: hyperkalemia (especially when combined with ACE inhibitors or NSAIDs).

Perioperative Anticoagulant & Antiplatelet Management

Podiatric surgeons routinely manage complex patients undergoing elective foot and ankle reconstructions, trauma ORIF, or limb salvage who are receiving chronic antiplatelet or anticoagulant therapy. Balancing thromboembolic prevention against intraoperative hemorrhage, wound hematoma, and compartment syndrome requires adherence to verified perioperative timelines.

Antiplatelet Pharmacology & Perioperative Timing

Anticoagulant Pharmacology, Monitoring & Reversal Protocols

High-Yield Anticoagulant Complications

---

Lipid-Lowering Pharmacotherapy (Statins)

HMG-CoA Reductase Inhibitors

• Representative Agents: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin.
• Molecular Mechanism: Statins act as structural analogs of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) and competitively inhibit HMG-CoA Reductase, the rate-limiting enzyme in hepatic de novo cholesterol biosynthesis ($HMG\text{-}CoA \rightarrow \text{Mevalonate}$).
• Downstream Cellular Cascade: Depletion of intracellular hepatic cholesterol triggers the activation of Sterol Regulatory Element-Binding Protein 2 (SREBP-2), which upregulates transcription of cell-surface LDL Receptors (LDL-R) on hepatocytes. Increased LDL receptor density drives massive endocytic clearance of circulating apoB-100-containing low-density lipoproteins, reducing serum LDL-C by $30\% - 60\%$.
• Pleiotropic Effects in Peripheral Artery Disease: Beyond lipid reduction, statins exert powerful pleiotropic vascular benefits: they improve endothelial function (upregulate eNOS), inhibit vascular smooth muscle proliferation, stabilize vulnerable atherosclerotic fibrous caps, and suppress inflammatory cytokines. High-intensity statin therapy reduces all-cause mortality, major adverse cardiovascular events (MACE), and major adverse limb events (MALE / amputations) in patients with peripheral artery disease.
• Adverse Effects & Drug Interactions:
  • Hepatotoxicity: Elevation in serum aminotransferases (AST/ALT); baseline LFTs checked prior to initiation.
  • Statin-Associated Muscle Symptoms (SAMS) & Rhabdomyolysis: Manifests as bilateral proximal muscle weakness, soreness, and myalgias. In severe cases, it progresses to rhabdomyolysis, marked by massive elevations in serum creatine kinase ($CK > 10\text{x}$ upper limit of normal), dark tea-colored urine (myoglobinuria), and acute tubular necrosis.
  • CYP3A4 Drug-Drug Interactions: Simvastatin, lovastatin, and atorvastatin are metabolized extensively by hepatic Cytochrome P450 3A4 (CYP3A4). Concomitant administration of potent CYP3A4 inhibitors—particularly azole antifungals (itraconazole, ketoconazole, fluconazole), macrolide antibiotics (erythromycin, clarithromycin), protease inhibitors, or gemfibrozil (which inhibits statin glucuronidation)—markedly reduces statin clearance, escalating plasma concentrations by up to 10-fold and precipitating severe, life-threatening rhabdomyolysis. In patients requiring systemic azole therapy for onychomycosis or deep mycotic foot infections, statins must be temporarily held or switched to pravastatin or rosuvastatin (which are not metabolized via CYP3A4).

Cardiac Glycosides, Antiarrhythmics, Antianginals, Vasodilators & Fibrinolytics

The pharmacology outline's cardiovascular heading also lists cardiac glycosides, antiarrhythmics, antianginals, fibrinolytics and vasodilators.

Digoxin (cardiac glycoside).

• Mechanism: inhibits the Na+/K+-ATPase. Intracellular Na+ rises, the Na+/Ca2+ exchanger removes less calcium, and contractility increases. Digoxin also raises vagal tone, slowing AV conduction, which is why it is used for rate control in atrial fibrillation.
• Toxicity: nausea and vomiting, confusion, yellow-green visual halos and arrhythmias such as atrial tachycardia with block or bidirectional ventricular tachycardia. It has a narrow therapeutic index.
• Risk factors: hypokalemia from loop or thiazide diuretics (potassium normally competes with digoxin at the pump), renal impairment, and interacting drugs such as amiodarone, verapamil and clarithromycin.
• Antidote: digoxin immune Fab. Hyperkalemia signals severe acute toxicity.

Antiarrhythmics (Vaughan Williams classes):

Antianginals.

• Nitrates (nitroglycerin, isosorbide mononitrate) release nitric oxide, which raises cGMP and dilates veins, reducing preload and myocardial oxygen demand. Adverse effects include headache, hypotension and reflex tachycardia. Tolerance requires a daily nitrate-free interval. Nitrates are contraindicated with PDE5 inhibitors (sildenafil, tadalafil) because together they cause severe hypotension.
• Beta-blockers lower heart rate and contractility, calcium channel blockers lower afterload and relieve coronary spasm, and ranolazine inhibits the late sodium current.

Vasodilators.

• Hydralazine is an arteriolar dilator. It causes reflex tachycardia, fluid retention and drug-induced lupus. Combined with isosorbide dinitrate, it benefits Black patients with heart failure with reduced ejection fraction.
• Minoxidil opens K-ATP channels. It causes edema, hypertrichosis and pericardial effusion.
• Nitroprusside dilates both arteries and veins. Prolonged infusion can cause cyanide toxicity.

Drugs for claudication and PAD.

• Cilostazol is a PDE3 inhibitor that dilates arteries, inhibits platelets and improves walking distance. It carries a boxed warning against use in heart failure of any severity, and CYP3A4 and CYP2C19 inhibitors raise its levels.
• Pentoxifylline is no longer recommended for claudication because it is not effective.
• Statins and antiplatelet therapy reduce cardiovascular events in PAD. Low-dose rivaroxaban (2.5 mg twice daily) with aspirin reduces major cardiovascular and limb events.

Fibrinolytics.

• Alteplase and tenecteplase convert plasminogen to plasmin, which degrades fibrin.
• Uses include acute ischemic stroke, STEMI when timely PCI is unavailable, massive pulmonary embolism and catheter-directed treatment of acute limb ischemia.
• The major risk is bleeding, including intracranial hemorrhage. Contraindications include active bleeding, prior hemorrhagic stroke and recent major surgery or trauma.
• Bleeding is managed by stopping the infusion and giving cryoprecipitate (fibrinogen) and an antifibrinolytic such as tranexamic acid or aminocaproic acid.